NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

19.04.2024 - TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) - NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Lior Shaltiel, CEO and Director ... Seite 1

Related Keywords

Germany ,Canada ,London ,City Of ,United Kingdom ,Exosomes Europe ,Eva Reuter ,Lior Shaltiel ,Nurexone Biologic Inc ,Thesis Capital Inc ,Facebook ,Exone Biologic ,Central Nervous System ,Orphan Drug Designation ,Executive Officer ,Nurexone Biologic Chart ,Urexone Biologic Kurs ,Urexone Biologic Aktie ,